3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Neoplasms
2
Mycosis Fungoides
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Interventions
Cyclophosphamide
166
Docetaxel
154
Bevacizumab
153
Carboplatin
148
Gemcitabine
146
Cisplatin
146
pembrolizumab
144
Radiotherapy
135
Paclitaxel
132
Capecitabine
122
Rituximab
115
Oxaliplatin
104
Fluorouracil
103
Nivolumab
94
Irinotecan
85
Doxorubicin
85
Pemetrexed
83
Leucovorin
82
Dexamethasone
82
fludarabine
74
fludarabine phosphate
72
Bortezomib
69
Etoposide
67
Erlotinib Hydrochloride
66
Cetuximab
65
Methotrexate
58
Trastuzumab
56
Cytarabine
54
Lenalidomide
50
Everolimus
49
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Terminated
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled